These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 31571848

  • 1. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [Abstract] [Full Text] [Related]

  • 2. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.
    Choi KY, Kim HI, Rhee CK, Yoo KH, Park YB, Kim Y, Lee SE, Kim JA, Hwang YI.
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1661-1671. PubMed ID: 39050737
    [Abstract] [Full Text] [Related]

  • 3. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS, Landis SH, Wurst K, Le H.
    Respir Res; 2015 Nov 16; 16():141. PubMed ID: 26572740
    [Abstract] [Full Text] [Related]

  • 4. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 16; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 5. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.
    Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 16; 14():343-352. PubMed ID: 30863037
    [Abstract] [Full Text] [Related]

  • 6. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS, DePietro M, McPheeters J, Fox KM.
    Ther Adv Respir Dis; 2018 Nov 16; 12():1753466618772750. PubMed ID: 29737943
    [Abstract] [Full Text] [Related]

  • 7. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.
    Int J Chron Obstruct Pulmon Dis; 2012 Nov 16; 7():201-9. PubMed ID: 22500120
    [Abstract] [Full Text] [Related]

  • 8. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr 16; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 9. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E.
    Respir Med; 2018 Sep 16; 142():73-80. PubMed ID: 30170806
    [Abstract] [Full Text] [Related]

  • 10. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K, Silva Miguel L, Hillas G, Borges M, Papageorgiou G, Viana D, Malhadeiro J, Soulard S.
    Ther Adv Respir Dis; 2020 Sep 16; 14():1753466620926802. PubMed ID: 32519591
    [No Abstract] [Full Text] [Related]

  • 11. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
    Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J, Juárez M, Graefenhain R, Sicras-Mainar A.
    Chest; 2022 Nov 16; 162(5):1017-1029. PubMed ID: 35787391
    [Abstract] [Full Text] [Related]

  • 12. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
    Lee CH, Kim MS, Yeo SH, Rhee CK, Park HW, Yang BR, Lee J, Cho EY, Xu X, Navarro Rojas AA, Shantakumar S, Milea D, Choi NK.
    Respir Res; 2022 Sep 05; 23(1):231. PubMed ID: 36064539
    [Abstract] [Full Text] [Related]

  • 13. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH, Yang TM, Lin CM, Huang SY, Wen YW.
    Int J Chron Obstruct Pulmon Dis; 2017 Sep 05; 12():2787-2793. PubMed ID: 29026296
    [Abstract] [Full Text] [Related]

  • 14. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD.
    Respir Res; 2019 Nov 04; 20(1):242. PubMed ID: 31684965
    [Abstract] [Full Text] [Related]

  • 15. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers.
    Wittbrodt ET, Millette LA, Evans KA, Bonafede M, Tkacz J, Ferguson GT.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 04; 14():101-114. PubMed ID: 30613140
    [Abstract] [Full Text] [Related]

  • 16. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W, Wood R, Jakubanis R, Holbrook T, Bizouard G, Despres J, Silva CCD, Nachbaur G, Landis SH, Punekar Y, Aguilaniu B, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 04; 14():51-63. PubMed ID: 30587961
    [Abstract] [Full Text] [Related]

  • 17. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J.
    J Manag Care Spec Pharm; 2020 Oct 04; 26(10):1363-1374. PubMed ID: 32678719
    [Abstract] [Full Text] [Related]

  • 18. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 04; 13():781-792. PubMed ID: 29551894
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.
    Int J Chron Obstruct Pulmon Dis; 2012 Oct 04; 7():183-99. PubMed ID: 22500119
    [Abstract] [Full Text] [Related]

  • 20. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 04; 13():3971-3981. PubMed ID: 30587953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.